Forum Markets Reports Third Quarter 2026 Financial Results

FORUM MARKETS Inc (FRMM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Forum Markets Reports Third Quarter 2026 Financial Results Updates 2026 Guidance and Maintains 2027 Revenue Outlook PALM BEACH, Fla., Nov. 12, 2026 /PRNewswire/ — Forum Markets, Incorporated (Nasdaq: FRMM) (“Forum” or the “Company”), an innovator in sourcing and oper

Original reporting
Published Nov 12, 2026, 1:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$FRMM
Bearish
medium confidence
Mentioned
$FRMM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FRMMBearishMed
01

Why it matters

The revised 2026 revenue guidance reflects slower AI compute deployment and higher equipment costs, shifting revenue reliance to aircraft engine leases.

02

Market read

Guidance updated may trigger sell pressure in FRMM shares; investors will watch AI compute deployment progress.

03

What to watch

The strong net income from digital asset gains and the new joint venture may offset revenue shortfall in the longer term.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Forum Markets Inc. (Nasdaq: FRMM) focuses on AI infrastructure, commercial aerospace leasing, and AI‑powered consumer finance.

Company-level read

Ticker impact

$FRMMBearishMedium confidence
Context

Forum Markets reported Q3 2026 results and updated full-year 2026 revenue guidance to $8M-$9M from $18M-$22M.

Expected impact

likely pressure as the market prices in the updated guidance

Evidence & confidence

Revenue guidance updated by more than 50% signals weaker growth, which may prompt short sellers and deter buyers.

Market effects

AI infrastructure and commercial aerospace sectors may see heightened scrutiny on cash‑generating asset models.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact given the company's small size.

Counterpoint

If the company successfully deploys its AI compute capacity later, the guidance cut could be temporary and present a buying opportunity.

Key entities

  • Forum Markets Inc.

    Issuer of the 8‑K filing reporting Q3 results and guidance update.

  • McAndrew Rudisill

    Chairman and CEO who commented on the company's strategic focus.

Related articles

$FRMMMedAI 8/10

Forum Edge AI Announces $94.4 Million Definitive AI Cloud Services Compute Agreement with Fireworks

FORUM MARKETS Inc (FRMM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Forum Edge AI Announces $94.4 Million Definitive AI Cloud Services Compute Agreement with Fireworks PALM BEACH, Fla., Oct. 26, 2026 /PRNewswire/ — Forum Markets, Incorporated (“Forum” or “the Company”) (Nasdaq: FRMM), an innovator in sourcing and operating cash-gener

$FRMMMedAI 8/10

Forum Markets Reports Second Quarter 2026 Financial Results

Forum Markets (Nasdaq: FRMM) reported Q2 2026 revenue of about $1.4M, down from $2.9M in Q1, citing elimination of $1.8M digital asset staking revenue after selling most Ether in March. It repurchased about 7.1M shares (35%) at $4.42/share. Full-year 2026 revenue guidance remains $18M to $22M.

$MOVEMed

Corvex Reports Third Quarter 2026 Results

Corvex, Inc. (MOVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corvex Reports Third Quarter 2026 Results ARLINGTON, Va., Nov. 12, 2026 /PRNewswire/ -- Corvex, Inc. (Nasdaq: MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today reported financial results for the thi

$AVLNMed

Avalyn Pharma 3Q 2026: EPS ($0.67) — 10-Q Summary

Avalyn Pharma reported a wider net loss of $29.66M in Q3 2026, up 25.7% YoY, driven by higher R&D and administrative expenses. Diluted EPS was ($0.67). The company provided updates on clinical trials for AP01, AP02, and AP03, with topline data expected in late 2027. R&D costs increased by $3.4M, primarily due to AP02 trial expenses.